Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%

Lignende værker

• Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
  af: Kosuke Hashimoto, et al.
  Udgivet: (2020-03-01)
• Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
  af: Hashimoto, Kosuke, et al.
  Udgivet: (2020)
• Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review
  af: MOURI, ATSUTO, et al.
  Udgivet: (2020)
• Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
  af: Yamaguchi, Ou, et al.
  Udgivet: (2020)
• Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
  af: Atsuto Mouri, et al.
  Udgivet: (2019-04-01)